KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Assets for 15 consecutive years, with 0.23% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Assets changed N/A to 0.23% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.23%, a N/A change, with the full-year FY2024 number at 0.23%, up 8.0% from a year prior.
  • Return on Assets was 0.23% for Q1 2025 at Halozyme Therapeutics, up from 0.21% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.23% in Q2 2021 to a low of 0.09% in Q4 2021.
  • A 5-year average of 0.16% and a median of 0.16% in 2023 define the central range for Return on Assets.
  • Biggest YoY gain for Return on Assets was 36bps in 2021; the steepest drop was -14bps in 2021.
  • Halozyme Therapeutics' Return on Assets stood at 0.09% in 2021, then grew by 18bps to 0.11% in 2022, then soared by 42bps to 0.16% in 2023, then surged by 37bps to 0.21% in 2024, then grew by 7bps to 0.23% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Return on Assets are 0.23% (Q1 2025), 0.21% (Q4 2024), and 0.16% (Q4 2023).